Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162483

SCHEMBL10162483

SCHEMBL10162483

CC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3ccc(F)cc3)nc3ccnn23)cc1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ THRB P10828 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ MMP13 P45452 2/20 0.44
▸ TP53 P04637 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ADORA2A P29274 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10165684 0.91 SMN1; SMN2 (0.48) POLBSMN1; SMN2THRBALDH1A1L3MBTL1
SCHEMBL10162460 0.91 MMP13 (0.45) L3MBTL1MMP13
SCHEMBL10162440 0.89 POLB (0.45) POLBSMN1; SMN2THRBALDH1A1L3MBTL1
SCHEMBL10162464 0.89 MMP13 (0.53) SMN1; SMN2L3MBTL1MMP13
SCHEMBL10162467 0.88 MAPK1 (0.43) MMP13LMNA
SCHEMBL10162361 0.86 AKT3 (0.43) POLBSMN1; SMN2THRBALDH1A1L3MBTL1
SCHEMBL8253247 0.86 POLB (0.46) POLBSMN1; SMN2THRBALDH1A1L3MBTL1
SCHEMBL8256456 0.86 KMT2A (0.48) POLBSMN1; SMN2THRBALDH1A1L3MBTL1
SCHEMBL10162477 0.85 MEN1 (0.50) MMP13LMNA
SCHEMBL10165648 0.84 EGLN1 (0.46) POLBSMN1; SMN2THRBALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885THRB 4683/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885THRB 4683/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885THRB 4683/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885THRB 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.